2015
IL-17 Inhibition in Axial Spondyloarthritis
Danve A, Deodhar A. IL-17 Inhibition in Axial Spondyloarthritis. Current Treatment Options In Rheumatology 2015, 1: 221-230. DOI: 10.1007/s40674-015-0020-9.Peer-Reviewed Original ResearchIL-23/ILIL-17IL-23Monoclonal antibodiesExtra-articular manifestationsTNF-α blockadeIL-17 inhibitionIL-23 receptorQuality of lifeSignificant beneficial effectDisease activityProspective trialRadiographic progressionInhibitor medicationIL-12MRI scoresPhysical functionAxial spondyloarthritisClinical studiesP40 subunitAnimal modelsBeneficial effectsWestern populationsNovel optionSpondyloarthritis
2014
AB0677 Routine Assessment of Patient Index Data 3 Scores Correlate Well with Bath Ankylosing Spondylitis Disease Activity Index in the Assessment of Disease Activity and Monitoring Progression of Ankylosing Spondylitis
Danve A, Reddy A, Vakil-Gilani K, Dinno A, Deodhar A. AB0677 Routine Assessment of Patient Index Data 3 Scores Correlate Well with Bath Ankylosing Spondylitis Disease Activity Index in the Assessment of Disease Activity and Monitoring Progression of Ankylosing Spondylitis. Annals Of The Rheumatic Diseases 2014, 73: 1029. DOI: 10.1136/annrheumdis-2014-eular.1321.Peer-Reviewed Original ResearchBath Ankylosing Spondylitis Disease Activity IndexSpondylitis Disease Activity IndexDisease activity indexDisease activityRheumatoid arthritisRheumatic diseasesBaseline Bath Ankylosing Spondylitis Disease Activity IndexRoutine assessmentDisease Activity Score 28Patient Index Data 3Activity indexElectronic medical record searchPatient global assessmentMedical record searchRAPID3 scoresScore 28Disease durationPatient functionRheumatology practicePhysical functionRAPID3PatientsRecord searchGlobal assessmentBusy practice